Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gildeuretinol - Alkeus Pharmaceuticals/Columbia University

Next Previous
Drug Profile

Gildeuretinol - Alkeus Pharmaceuticals/Columbia University

Alternative Names: ALK-001; C20-D3-Retinyl Acetate; C20-D3-vitamin A; Deuterated-retinol; Deuterated-vitamin-A; Gildeuretinol acetate; Vitamin-A-deuterated

Latest Information Update: 17 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University
  • Developer Alkeus Pharmaceuticals
  • Class Eye disorder therapies; Retinoids; Vitamins
  • Mechanism of Action Dimerisation inhibitors; Vitamin A replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stargardt disease
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration
  • Phase II Stargardt disease
  • No development reported Retinal dystrophies

Most Recent Events

  • 09 Jan 2025 Alkeus Pharmaceuticals announces intention to submit an NDA to US FDA for Stargardt disease in 2025
  • 09 Jan 2025 Efficacy and adverse event data from phase II trial for Stargardt disease released by Alkeus Pharmaceuticals
  • 09 Jan 2025 Alkeus Pharmaceuticals plans clinical TEASE-4 trial for Stargardt disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top